Q4 2025 Management View CEO Joseph Ciaffoni stated that 2025 was a transition year, highlighting the successful completion of Phase I Generate Momentum and the delivery of record net revenue for ...

Attributed 2025 performance to improved commercial execution and record SUBLOCADE net revenue of $856 million, a 13% year-over-year increase. Simplified the organizational structure to establish a ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". Health Canada Grants Priority Review Designation for SUBLOCADE™ SLOUGH, ...

Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net ...

Indivior (NASDAQ:INDV) executives told investors the company’s 2025 performance reflected a “transition year” marked by ...

Indivior PLC is set to report fourth-quarter and full-year 2025 results before the market opens Thursday, February 26, as Wall Street looks for evidence the addiction-treatment specialist can deliver ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches ...

SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered ...

Please provide your email address to receive an email when new articles are posted on . New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs.

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...